Meso
Emerging
Active
Analysts weigh in on NVST's potential
New narrative with limited coverage — still forming.
Score
0.2
Velocity
▲ 0.0
Articles
4
Sources
1
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Health Care | -0.3% |
Sentiment Timeline
Sector Performance
Event Timeline
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Health Care | -0.3% |
🤖
AI Overview
What happened: Envista Holdings (NVST) gained analyst attention in Q1 2026. Aristotle Capital picked NVST for its varied growth signals, while Morgan Stanley raised its price target to $21, maintaining an 'Equal Weight' rating. Ariel Investments highlighted NVST's earnings beat and accelerating market share gains.
Market impact: The dental products and services provider's strong performance is driving interest in the medical sector. NVST's stock price reacted positively to the earnings beat and analyst upgrades, benefiting investors and potentially attracting more capital.
What to watch next: Upcoming catalysts include NVST's Q2 2026 earnings release (scheduled for late July), further analyst coverage, and any regulatory changes affecting the dental industry. Additionally, monitor NVST's stock price action around the $21 price target set by Morgan Stanley.
Market impact: The dental products and services provider's strong performance is driving interest in the medical sector. NVST's stock price reacted positively to the earnings beat and analyst upgrades, benefiting investors and potentially attracting more capital.
What to watch next: Upcoming catalysts include NVST's Q2 2026 earnings release (scheduled for late July), further analyst coverage, and any regulatory changes affecting the dental industry. Additionally, monitor NVST's stock price action around the $21 price target set by Morgan Stanley.
AI Overview as of May 21, 2026
Timeline
First SeenJul 04, 2026
Last UpdatedAug 28, 2026